×

SAGE to Present Data at Upcoming Scientific Conferences

CAMBRIDGE, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced upcoming data poster presentations at the 13th Annual Neurocritical Care Society Meeting, taking place October 7-10 in Scottsdale, Arizona, and at the Society for Neuroscience Annual Meeting, taking place October 17-21 in Chicago, Illinois.

The schedule for the poster presentations is as follows:

13th Annual Neurocritical Care Society Meeting

Date: Thursday, October 8, 2015
Presentation Time: From 6:00 p.m. to 7:00 p.m. MST
Location: Kierland Grand Ballroom, Westin Kierland Resort & Spa, Scottsdale, Arizona
Title: Quantitative Burst Suppression as a Biomarker in the Phase 1/2 Trial of SAGE-547: Lessons Learned for the First International Phase 3 Randomized Controlled Trial for Super-Refractory Status Epilepticus (the STATUS Trial)

Society for Neuroscience Annual Meeting - Neuroscience 2015

Date: Saturday, October 17, 2015
Presentation Time: From 1:00 p.m. to 5:00 p.m. CDT
Location: Hall A, McCormick Place, Chicago, Illinois
Title: SGE­516, A Novel Positive Allosteric Modulator of Synaptic and Extrasynaptic GABAA Receptors, Has an Anxiolytic­Like Effect In Vivo

Date: Tuesday, October 20, 2015
Presentation Time: From 8:00 a.m. to 12:00 p.m. CDT
Location: Hall A, McCormick Place, Chicago, Illinois
Title: Efficacy of a Second Generation Neuroactive Steroid, SAGE-217, in a Mouse Model of Chronic Medial Temporal Lobe Epilepsy

About Sage Therapeutics
Sage Therapeutics (NASDAQ:SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients living with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

Investor Contact: Paul Cox, Sage Therapeutics paul.cox@sagerx.com 617-299-8377 Media Contact: Dan Budwick, Pure Communications dan@purecommunicationsinc.com 973-271-6085

Source:SAGE Therapeutics